"FDA Approves Imbruvica As First Therapy For Chronic Graft-Versus-Host Disease" - James L.M. Ferrara, MD, DSc
The FDA approved ibrutinib for the treatment of adults with chronic graft-versus-host disease who failed prior systemic therapy. “Chronic GVHD is a major toxicity of bone marrow transplant, which is one of the most effective therapies we have for high-risk malignancies. Both patients and physicians are reluctant to undertake transplantation, not only because of its initial intensity, but because of some of the long-term toxicities. Even if patients are cured of their leukemia or lymphoma, they can end up with this immune-mediated disease that can affect their skin, liver, lungs, gastrointestinal tract and joints. When it is severe, it can be fatal. It is the dark side of the therapy,” says author of perspective James L. M. Ferrara, MD, professor of oncological sciences at the Icahn School of Medicine at Mount Sinai
- James L.M. Ferrara, MD, Professor of Pediatrics, Oncological Sciences and Medicine, Hematology and Medical Oncology at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, and Co-director of Mount Sinai Acute GVHD International Consortium (MAGIC)
Additional coverage:
Mount Sinai Receives $10 Million Grant to Study Graft vs. Host Disease
Oct 13, 2016 View All Press Releases